Molecular Dynamics MegaBACE 1000 DNA sequencer sales ramp-up depends on initial market acceptance.
This article was originally published in The Gray Sheet
Executive SummaryMOLECULAR DYNAMICS MEGABACE 1000 DNA SEQUENCER FULL-SCALE LAUNCH is contingent on the level of market acceptance in the second phase of the company's three-stage roll-out strategy, the company says. "During the latter part of 1998, we will go into the broader market launch of this product, but that will depend on the level of demand we experience in" the ongoing phase-two marketing, President and CEO Jay Flatley told investors at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco.
You may also be interested in...
The North American trade organization’s new website offers consumers a gateway into the world of fragrance. Providing a “deep dive” into 50 fragrance ingredients, as well as overviews of perfumery, key regulations, and industry safety practices and sustainability efforts, the site extends FCA’s work to engage and inform consumers at a time of growing interest in manufactured scents.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.